Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Scheduled for April 2, 2024

Unlocking the Power of the Adaptive Immune System: A Business Update from Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a biotechnology company listed on the Nasdaq under the ticker symbol ADPT, is dedicated to translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases. The company recently announced that it will be hosting a business update conference call and webcast on Tuesday, April 2, 2024, after the market closes at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies believes that the adaptive immune system is a powerful tool for diagnosing and treating most diseases but has not been fully utilized due to the challenges of decoding it. The company’s immune medicine platform enables the decoding of the genetics of the adaptive immune system with scale, precision, and speed. Adaptive Biotechnologies collaborates with biopharmaceutical companies, informs drug development, and develops clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Their products and pipeline aid in diagnosing, monitoring, and treating diseases such as cancer, autoimmune disorders, and infectious diseases with the goal of developing personalized immune-driven clinical products for each patient.

The live audio of the webcast will be available on the “Investors” section of the company website at The webcast will also be archived for replay within 24 hours after the event. For inquiries from investors, Karina Calzadilla, Vice President of Investor Relations, can be reached at For media inquiries, contact Erica Jones, Associate Director of Corporate Communications


As a content writer at, I am Samantha Johnson—a wordsmith with a fervent love for storytelling and a keen eye for captivating readers. With a diverse background in journalism and digital marketing, I craft compelling narratives that engage, inform, and inspire our audience. Whether unraveling breaking news stories or delving into thought-provoking features, my aim is to deliver content that resonates and leaves a lasting impact. Join me on a journey through the ever-evolving landscape of news and narratives at